693792-99-3 Usage
Uses
Used in Organic Synthesis:
(2-((4-(Tert-Butoxycarbonyl)benzyl)aMino)phenyl)boronic acid is used as a reagent in organic synthesis for its ability to participate in Suzuki-Miyaura cross-coupling reactions, enabling the formation of carbon-carbon bonds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2-((4-(Tert-Butoxycarbonyl)benzyl)aMino)phenyl)boronic acid is used as a building block for the synthesis of various pharmaceuticals and bioactive molecules, contributing to the development of new therapeutic agents.
Used in Pharmaceutical Development:
(2-((4-(Tert-Butoxycarbonyl)benzyl)aMino)phenyl)boronic acid is used as a key component in the development of protease inhibitors and other therapeutic agents, highlighting its potential in creating novel treatments for various diseases.
Used in the Synthesis of Bioactive Molecules:
(2-((4-(Tert-Butoxycarbonyl)benzyl)aMino)phenyl)boronic acid is also utilized in the synthesis of bioactive molecules, which can have significant applications in the pharmaceutical industry for the creation of new drugs and therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 693792-99-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,9,3,7,9 and 2 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 693792-99:
(8*6)+(7*9)+(6*3)+(5*7)+(4*9)+(3*2)+(2*9)+(1*9)=233
233 % 10 = 3
So 693792-99-3 is a valid CAS Registry Number.
693792-99-3Relevant articles and documents
PHENYL OR HETEROARYL AMINO ALKANE DERIVATIVES AS IP RECEPTOR ANTAGONIST
-
Page 117-118, (2010/02/07)
The present invention relates to a phenyl or heteroaryl amino alkane derivatives which are useful as an active ingredient of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the diseases also is alleviated by treatment with an IP receptor antagonist.
